Empasug ST 100/25
MRP: 2,250
Packaging: 10X10
Pack Type: tablet
Composition:
Empagliflozin 25 mg + Sitagliptin 100 mg
Indication:
Used in adults with type 2 diabetes mellitus (T2DM) to improve blood sugar control as an adjunct to diet and exercise. Combines SGLT2 inhibitor (Empagliflozin) and DPP-4 inhibitor (Sitagliptin) for dual glucose-lowering action. Not for type 1 diabetes or diabetic ketoacidosis.
Description:
Empagliflozin 25mg + Sitagliptin 100mg is a fixed-dose combination tablet designed for the treatment of type 2 diabetes mellitus. This combination merges two powerful antidiabetic agents:
Empagliflozin (25mg): A Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor that lowers blood glucose by promoting the elimination of glucose via urine.
Sitagliptin (100mg): A Dipeptidyl Peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release in response to meals.
Together, these medications provide complementary mechanisms to improve glycemic control, reduce blood sugar levels, support weight management, and lower the risk of cardiovascular complications often seen in type 2 diabetes patients.
Tags:
- Dual mechanism effectively controls blood glucose
- Supports weight management and cardiovascular health
- Convenient once-daily dosing
- Lowers risk of hypoglycemia
- Enhances overall glycemic control
Usage Information
Dosage
Take one tablet once daily, with or without food. Follow your healthcare provider’s directions carefully. Maintain adequate hydration while on treatment.
Side Effects
Common side effects: Increased urination Nasopharyngitis (common cold symptoms) Headache Urinary tract infections Gastrointestinal discomfort Serious but rare side effects: Diabetic ketoacidosis Pancreatitis Severe allergic reactions
Contraindications
Type 1 diabetes and diabetic ketoacidosis Severe renal impairment (eGFR < 30 mL/min/1.73m²) Known hypersensitivity to Empagliflozin, Sitagliptin, or excipients History of pancreatitis (use cautiously) Pregnancy and breastfeeding (consult doctor)